Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

• Main Authors: Abundio Balgos (Author), Suad Hannawi (Author), Wen-Li Chen (Author), Alaa Abuquta (Author), Linda Safeldin (Author), Aala Hassan (Author), Ahmad Alamadi (Author), Louie Tirador (Author), Anjuli May Jaen (Author), Ralph Elvi Villalobos (Author), Chen Mo (Author), Zi-Jing Yue (Author), Ying Ma (Author), Qing-Shuang Wang (Author), Ren-Du Wen (Author), Zheng Yao (Author), Jia-Ping Yu (Author), Wen-Rong Yao (Author), Jian-Hui Zhang (Author), Kun-Xue Hong (Author), Yong Liu (Author), Jing-Xin Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTBackground Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.Research design and methods Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivate...